Related references
Note: Only part of the references are listed.The role of vascular endothelial growth factor in the hypoxic and immunosuppressive tumor microenvironment: perspectives for therapeutic implications
Ryota Tamura et al.
MEDICAL ONCOLOGY (2020)
Clinical and histopathological analyses of VEGF receptors peptide vaccine in patients with primary glioblastoma-a case series
Ryota Tamura et al.
BMC CANCER (2020)
A VEGF receptor vaccine demonstrates preliminary efficacy in neurofibromatosis type 2 (vol 10, pg 5758, 2019)
Ryota Tamura et al.
NATURE COMMUNICATIONS (2020)
Tumor Development and Angiogenesis in Adult Brain Tumor: Glioblastoma
Bhavesh K. Ahir et al.
MOLECULAR NEUROBIOLOGY (2020)
Effect of Nivolumab vs Bevacizumab in Patients With Recurrent Glioblastoma The CheckMate 143 Phase 3 Randomized Clinical Trial
David A. Reardon et al.
JAMA ONCOLOGY (2020)
Synergistic effect of immune checkpoint blockade and anti-angiogenesis in cancer treatment
Ming Yi et al.
MOLECULAR CANCER (2019)
A Pilot Study of Vaccine Therapy with Multiple Glioma Oncoantigen/Glioma Angiogenesis-Associated Antigen Peptides for Patients with Recurrent/Progressive High-Grade Glioma
Ryogo Kikuchi et al.
JOURNAL OF CLINICAL MEDICINE (2019)
Efficacy and safety of bevacizumab for vestibular schwannoma in neurofibromatosis type 2: a systematic review and meta-analysis of treatment outcomes
Victor M. Lu et al.
JOURNAL OF NEURO-ONCOLOGY (2019)
Persistent restoration to the immunosupportive tumor microenvironment in glioblastoma by bevacizumab
Ryota Tamura et al.
CANCER SCIENCE (2019)
A pilot study of peptide vaccines for VEGF receptor 1 and 2 in patients with recurrent/progressive high grade glioma
Shunsuke Shibao et al.
Oncotarget (2018)
Toxicity profile of bevacizumab in the UK Neurofibromatosis type 2 cohort
Katrina A. Morris et al.
JOURNAL OF NEURO-ONCOLOGY (2017)
Targeting cellular pathways in glioblastoma multiforme
Joshua R. D. Pearson et al.
SIGNAL TRANSDUCTION AND TARGETED THERAPY (2017)
Bevacizumab for malignant gliomas: current indications, mechanisms of action and resistance, and markers of response
Ryota Tamura et al.
BRAIN TUMOR PATHOLOGY (2017)
Dual antiangiogenic inhibition: a phase I dose escalation and expansion trial targeting VEGF-A and VEGFR in patients with advanced solid tumors
Gerald S. Falchook et al.
INVESTIGATIONAL NEW DRUGS (2015)
Dual VEGF/VEGFR inhibition in advanced solid malignancies Clinical effects and pharmacodynamic biomarkers
Kriti Mittal et al.
CANCER BIOLOGY & THERAPY (2014)
A Randomized Trial of Bevacizumab for Newly Diagnosed Glioblastoma
Mark R. Gilbert et al.
NEW ENGLAND JOURNAL OF MEDICINE (2014)
Bevacizumab for Newly Diagnosed Glioblastoma Reply
Olivier L. Chinot et al.
NEW ENGLAND JOURNAL OF MEDICINE (2014)
Bevacizumab plus Radiotherapy-Temozolomide for Newly Diagnosed Glioblastoma
Olivier L. Chinot et al.
NEW ENGLAND JOURNAL OF MEDICINE (2014)
Phase III Randomized Trial Comparing the Efficacy of Cediranib As Monotherapy, and in Combination With Lomustine, Versus Lomustine Alone in Patients With Recurrent Glioblastoma
Tracy T. Batchelor et al.
JOURNAL OF CLINICAL ONCOLOGY (2013)
Multicenter, phase II clinical trial of cancer vaccination for advanced esophageal cancer with three peptides derived from novel cancer-testis antigens
Koji Kono et al.
JOURNAL OF TRANSLATIONAL MEDICINE (2012)
Anti-angiogenic gene therapy in the treatment of malignant gliomas
NaTosha N. Gatson et al.
NEUROSCIENCE LETTERS (2012)
Risks and benefits with bevacizumab: evidence and clinical implications
Carla Kurkjian et al.
THERAPEUTIC ADVANCES IN DRUG SAFETY (2012)
Phase II study of sunitinib malate in patients with recurrent high-grade glioma
B. Neyns et al.
JOURNAL OF NEURO-ONCOLOGY (2011)
Toxicity of Sunitinib Plus Bevacizumab in Renal Cell Carcinoma
Brian I. Rini et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Phase II Study of Cediranib, an Oral Pan-Vascular Endothelial Growth Factor Receptor Tyrosine Kinase Inhibitor, in Patients With Recurrent Glioblastoma
Tracy T. Batchelor et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
A Phase I Study of Sunitinib plus Bevacizumab in Advanced Solid Tumors
Brian I. Rini et al.
CLINICAL CANCER RESEARCH (2009)
Phase I Trial of Bevacizumab Plus Escalated Doses of Sunitinib in Patients With Metastatic Renal Cell Carcinoma
Darren R. Feldman et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Hearing Improvement after Bevacizumab in Patients with Neurofibromatosis Type 2
Scott R. Plotkin et al.
NEW ENGLAND JOURNAL OF MEDICINE (2009)
Bevacizumab for recurrent malignant gliomas - Efficacy, toxicity, and patterns of recurrence
A. D. Norden et al.
NEUROLOGY (2008)
Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trial
Bernard Escudier et al.
LANCET (2007)
Angiogenesis in brain tumours
Rakesh K. Jain et al.
NATURE REVIEWS NEUROSCIENCE (2007)
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma
R Stupp et al.
NEW ENGLAND JOURNAL OF MEDICINE (2005)
VEGF inhibits T-cell development and may contribute to tumor-induced immune suppression
JE Ohm et al.
BLOOD (2003)
Vascular endothelial growth factor expression correlates with tumour grade and vascularity in gliomas
IH Chaudhry et al.
HISTOPATHOLOGY (2001)
Share Paper
